Scott Friedman

Has grant

Dean for Therapeutic Discovery

Icahn School of Medicine at Mount Sinai

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Scott Friedman is the Dean for Therapeutic Discovery at the Icahn School of Medicine at Mount Sinai, USA. His research focuses on liver diseases and encompasses areas such as antifibrotic therapies, cellular communication in lipid metabolism, and advances in diagnostics and therapeutics related to the extracellular matrix. He has published extensively on topics including liver fibrosis, CAR T-cell therapy, and the role of hepatic stellate cells in metabolic dysfunction-associated conditions.

Recent Grants

Grant: Close

Mechanisms of Acquired Resistance to Sorafenib in Hepatocellular Carcinoma

Open Date: 2014-10-01

Close Date: 2015-09-01

Grant: Close

Hepatic autophagy, Stem cells and Fibrosis

Open Date: 2000-05-01

Close Date: 2020-08-31

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (17)

Tobias Puengel

Charité - Universitätsmedizin Berlin

GERMANY

Scott Friedman

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (17)

Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease

Resolvin D1-mediated cellular crosstalk protects against MASH

Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases

Can we talk? The cryptic communications of hepatic stellate cells in lipid metabolism

Depletion of tumor-reactive HSCs reveals their significance during different stages of liver metastasis

Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics

Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis

Swept up in the tsunami: Pediatric and adolescent steatotic (fatty) liver disease

Aramchol improves hepatic fibrosis in metabolic dysfunction–associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology

Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome

Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction

Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions

Kisspeptin Alleviates Human Hepatic Fibrogenesis by Inhibiting TGFβ Signaling in Hepatic Stellate Cells

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Secreted folate receptor γ drives fibrogenesis in metabolic dysfunction–associated steatohepatitis by amplifying TGFβ signaling in hepatic stellate cells

Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)

Friend or foe? The elusive role of hepatic stellate cells in liver cancer

Collaborators (17)

Tobias Puengel

Brian Sansbury

Beatriz Arteta

Paresh Thakker

Andrea Heinz

Maryjka B. Blaszczyk

Utpal Pajvani

Ali Mobasheri

Carlos Barrero

Jerry Edward Chipuk

Alba Herrero Alonso

Federica Genovese

Alexander Eckersley

Corina Amor

Frank Tacke

Aitor Benedicto

Salim Merali

Make your next move.